Health care rationing in an age of uncertainty: A conceptual model

Social Science and Medicine

Volumn 72, Issue 8, 2011, Pages 1333-1341

  Moreira, Tiago ^a  

^a DURHAM UNIVERSITY   (United Kingdom)

Author keywords

Dementia drugs; Expertise and democracy; Health care rationing; National institute of health and clinical excellence (NICE); Public controversies; Sociology of science and technology; UK

Indexed keywords

CHOLINESTERASE INHIBITOR; NOOTROPIC AGENT;

CONCEPTUAL FRAMEWORK; DEMOCRACY; HEALTH CARE; MODELING; POLITICAL PROCESS; RATIONALIZATION; SCIENCE AND TECHNOLOGY;

ALZHEIMER DISEASE; ARTICLE; CASE STUDY; COST EFFECTIVENESS ANALYSIS; DEMENTIA; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HEALTH SERVICE; HUMAN; MEDICAL DECISION MAKING; NONBIOLOGICAL MODEL; POLITICS; PRESCRIPTION; QUALITY OF LIFE; SOCIOLOGY; UNITED KINGDOM;

ADVISORY COMMITTEES; DATABASES, FACTUAL; DEMENTIA; GREAT BRITAIN; HEALTH CARE RATIONING; HUMANS; MODELS, THEORETICAL; POLITICS; STATE MEDICINE; UNCERTAINTY;

UNITED KINGDOM;

EID: 79954977779     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.socscimed.2011.02.026     Document Type: Article

References (44)

1. A summary of the alzheimer's society's response to draft guidance from NICE 2005, Alzheimer's Society, Alzheimer's Society, London, May 2005.
2. Ballard C.G. Presentation on Alzheimers drugs to in house of. commons 2006, Alzheimer's Society, London.
3. Burns A., Howard R., Wilkinson R.G., Banerjee S. NICE draft guidance on the anti dementia drugs. BMJ 2005, London, Accessed 3 November 2009. http://www.bmj.com/content/330/7490/495.2/reply.
4. Callon M. Ni intellectuel engag', ni intellectuel d'gag': la double strat'gie de l'attachement et du d'tachement. Sociologie Du Travail 1999, 41(1):65-78.
5. Callon M. The role of lay people in the production and dissemination of scientific knowledge. Science, Technology and Society 1999, 4(1):81-94.
6. Callon M., Lascoumes P., Barthe Y. Acting in an uncertain world 2008, MIT Press, Cambridge MA.
7. Cambrosio A., Keating P., Schlich T., Weisz G. Regulatory objectivity and the generation and management of evidence in medicine. Social Science & Medicine 2006, 63(1):189-199.
8. Chalmers I. The alzheimer's society, drug manufacturers, and public trust. BMJ 2007, 335(7616):400.
9. Cookson R., Dolan P. Principles of justice in health care rationing. Journal of Medical Ethics 2000, 26(5):323-329.
10. Crinson I. The politics of regulation within the 'modernized' NHS: the case of beta interferon and the 'cost-effective' treatment of multiple sclerosis. Journal of Critical Social Policy 2004, 24(1):30-49.
11. Daniels N., Sabin J. Setting limits fairly 2008, Oxford University Press, New York.
12. Government response to NICE consultation on Alzheimer's drugs 2005, Department of Health, DoH, London.
13. Donaldson C., Bate A., Brambleby P., Waldner H. Moving forward on rationing: an economic view. BMJ 2008, 33:1872-1873.
14. Appraisal consultation document: Donepezil, rivastigmine, galantamine and memantine for the treatment of Alzheimer's disease 2006, NICE, NICE, London.
15. Reasonable rationing: International experience of priority setting in health care 2003, Open University Press, Maidenhead. C. Ham, G. Roberts (Eds.).
16. Hunter D. Desperately seeking solutions: rationing health care 1997, Longman, London.
17. Hope J. Elderly urged to target MPs over Alzheimer drugs ban 2005, Mail Online (Daily Mail), London.
18. Latour B. From the world of science to the world of research?. Science 1998, 280:208-209.
19. Latour B. Science in action 1987, Harvard University Press, Harvard.
20. Lancet T. Rationing is essential in tax-funded health systems. The Lancet 2006, 368:1394.
21. Light D.W., Hughes D. Introduction: a sociological perspective on rationing: power, rhetoric and situated practices. Sociology of Health & Illness 2001, 23(5):551-569.
22. Loveman E., Green C., Kirby J., Takeda A., Picot J., Bradbury J., et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine, and memantine for Alzheimer's disease 2005, Southamptoon Health Technology Assessment Centre, Southhampton.
23. Knight F. Risk, uncertainty and profit 1921, Houghton Mifflin, Boston.
24. Kurath M. Nanotechnology governance: accountability and democracy in new modes of regulation and deliberation. Science, Technology & Innovation Studies 2009, 5(2):87-110.
25. Mackenzie D. Inventing accuracy 1990, MIT Press, Cambridge MA.
26. Mechanic D. Muddling through elegantly: finding the proper balance in rationing. Health Affairs 1997, 16:83-92.
27. Meikle J. Minister intervenes in row over drugs to treat Alzheimer's 2005, The Guardian, London.
28. Milewa T. Health technology adoption and the politics of governance in the UK. Social Science & Medicine 2006, 63(12):3102-3112.
29. Moreira T. Diversity in clinical guidelines: the role of repertoires of evaluation. Social Science & Medicine 2005, 60:1975-1985.
30. Moreira T. 'Entangled evidence: knowledge making in systematic reviews in healthcare'. Sociology of Health and Illness 2007, 29(2):180-197.
31. Moreira T. Testing promises: truth and hope in drug development and evaluation in Alzheimer's disease. Do we have a pill for that? Interdisciplinary perspectives on the development, use and evaluation of drugs in the treatment of dementia 2009, Johns Hopkins University Press, Baltimore. J.F. Ballenger, P.J. Whitehouse, C. Lyketsos, P. Rabins, J.H.T. Karlawish (Eds.).
32. Moreira T., May C., Bond J. Regulatory objectivity in action: mild cognitive impairment and the collective production of uncertainty. Social Studies of Science 2009, 39(5):665-690.
33. Nowotny H., Scott P., Gibbons M. Re-thinking science: Knowledge and the public in an age of uncertainty 2001, Polity, Cambridge.
34. Porter T.M. Trust in numbers: The pursuit of objectivity in science and public life 1995, Princeton University Press, Princeton, NJ.
35. Implementation of the NICE guidance on donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease 2006, Royal College of Psychiatry, RCP, London.
36. Ragin C. Turning the tables: how case oriented research challenges variable oriented research. Rethinking social inquiry: Diverse tools, shared standards 2004, Rowman & Littlefield, Lanham. H. Brady, D. Collier (Eds.).
37. Rawlins M.D., Culyer A.J. National institute for clinical excellence and its value judgments. BMJ 2004, 329(7459):224-227.
38. Rip A. Controversies as informal technology assessment. Knowledge-Creation Diffusion Utilization 1986, 8(2):349-371.
39. Rose D. Controversy built into the job 2008, The Times, London.
40. Shapin S., Schaffer S. Leviathan and the air-pump: Hobbes, Boyle, and the experimental life 1985, Princeton University Press, Princeton NJ.
41. Sjögren E., Helgesson C.-F. The Q(u)ALYfying hand: health economics and medicine in the shaping of Swedish markets for subsidized pharmaceuticals. Market devices 2007, Wiley-Blackwell. M. Callon, Y. Millo, F. Muniesa (Eds.).
42. Timmermans S., Berg M. The gold standard: The challenge of EBM and standardization in medicine 2003, Temple Univeristy Press, Philadelphia.
43. Turnbull N., Shaw E.J., Baker R., Dunsdon S., Costin N., Britton G., et al. Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy): Diagnosis and management of chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy) in adults and children 2007, Royal College of General Practitioners, London.
44. Yin R. Case study research: Design and methods 2008, Sage, New York.